Sign in

NCT07817576Active, not recruiting

Serial Biomarker Testing and Cardiovascular Risk Stratification (ACHILLES)

Assessing Cardiovascular Hazard Via Intraindividual Biomarker Longitudinal Lability: an Evaluation of Serial Testing

Source: ClinicalTrials.gov · Last updated 14 Sept 2026

Brief summary (registry, in English)

The goal of this observational study is to learn how blood levels of biomarkers, e.g. hsCRP and Lp(a) - two markers linked to heart disease risk - change over time in patients who have had these levels tested more than once. The main questions it aims to answer are: How often does a high result on a first test return to normal on a later test? Do patients whose levels stay high across repeated tests have a higher risk of death than patients whose high level was only temporary

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
110000 (actual)
First submitted
2 Sept 2026
Start date
1 Jan 2004
Primary completion date
1 Jul 2025
Lead sponsor
University Hospital Freiburg
NCT number
NCT07817576

What you commit to

  • Study type: Observational
  • Participants enrolled: 110000
  • From 1 Jan 2004 to the primary completion date, 1 Jul 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • \- \< 18 years, Biomarker not available

Who the study is looking for

  • \- Available Biomarker Measurement

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Department of Cardiology - Freiburg - Bad Krozingen
Coordinator of this site? Confirm its status
Freiburg im BreisgauGermanyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.